This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.
The study indicated that the chemotherapy used was down to the physician's choice of either paclitaxel or doxorubicin.
Keytruda can now be used as first-line treatment in combination with chemotherapy – investigator’s choice of paclitaxel, nab-paclitaxel or gemcitabine/carboplatin – to treat locally recurrent unresectable or metastatic
Keytruda plus Lenvima treatment also led to an objective response rate (ORR) of 30% versus 15% for patients receiving either doxorubicin or paclitaxel. ... Patients receiving Merck and Eisai’s treatment had a complete response rate of 5% compared with 3
The EC approved Opdivo following positive results from the phase 3 ATTRACTION-3 trial, which investigated the PD-1 inhibitor versus chemotherapy docetaxel or paclitaxel – as a treatment for patients with
Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... The phase 3 Impassion131 study evaluated
The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer.
More from news
Approximately 9 fully matching, plus 122 partially matching documents found.
An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Current chemotherapy treatment options for ovarian cancer are fairly standard. After debulking surgery, the patient will undergo their first line of chemotherapy; the standard of care involves a combination of paclitaxel
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....